Indian Pharmaceutical Monthly Update July 2022.pdf

Indian Pharmaceutical Industry
Monthly Update
July 2022
Strictly Private and Confidential

2
Contents
1. Activity in Pharmaceutical Segment
2. Capital Market Performance – Pharmaceutical Industry
3. Edelweiss Credentials

3
Indian Pharmaceutical Sector News (1/2)
Source: Edelweiss Research, Press Releases
 Zydus Lifesciences has received USFDA approval for the following products:
o Empagliflozin and Metformin Hydrochloride Tablets in the strengths of 5 mg/500 mg, 5 mg/1000 mg, 12.5 mg/500
mg, and 12.5 mg/1000 mg
o Efinaconazole Topical Solution, 10%, used for the topical treatment of Onychomycosis of the toenails
o Norepinephrine Bitartrate Injection USP,4 mg/4 mL (1 mg/mL) Single-Dose Vial
o Bisoprolol Fumarate Tablets USP 5 mg and 10 mg, which are used to treat high blood pressure
 Aurobindo Pharma’s wholly-owned subsidiary, Eugia Pharma, has received USFDA approval to manufacture and market
Triamcinolone Acetonide Injectable Suspension 200 mg/5 mL & 400 mg/10 mL, to be bioequivalent and therapeutically
equivalent to the RLD, Kenalog-40 Injectable Suspension
 Lupin has received USFDA approval to market Azilsartan Medoxomil Tablets, 40 mg and 80 mg, generic equivalent of
Edarbi® Tablets
 Alembic Pharmaceuticals wholly-owned subsidiary, Aleor Dermaceuticals, has received USFDA approval for Diclofenac
Sodium Topical Gel, 3%, which is therapeutically equivalent to the RLD Solaraze Topical Gel, 3%
 Natco has received USFDA approval to market Cabazitaxel Intravenous Powder, 60mg/1.5mL (40mg/mL) strength, generic
equivalent for Jevtana Kit®
 Glenmark Pharmaceuticals has received USFDA approval to market Norethindrone Acetate and Ethinyl Estradiol Capsules
and Ferrous Fumarate Capsules, 1 mg/20 mcg, the generic version of Taytulla®1 Capsules
 Marksans Pharma has received USFDA approval for Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg,
225 mg, and 300 mg, which is bioequivalent and therapeutically equivalent to the RLD Lyrica Capsules
USFDA
APPROVALS

4
Indian Pharmaceutical Sector News (2/2)
Source: Edelweiss Research, Press Releases
 Dr. Reddy’s Laboratories has launched the following products:
o Bortezomib for injection, 3.5 mg single-dose vial in the US market
o Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz® (fesoterodine
fumarate) Extended-Release Tablets in the US
o OTC Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, the store-brand
equivalent of Allegra-D® 24 HR in the US
 Zydus Lifesciences has launched the molecule Sitagliptin in India under the brand names Sitaglyn® and Siglyn®, which is
used to treat Type 2 Diabetes
 Glenmark Pharmaceuticals has launched 8 different combinations of sitagliptin based drugs under the brand name
SITAZIT® and its variants
PRODUCT
LAUNCHES
 Dr. Reddy’s Laboratories has entered into a licensing agreement with Slayback Pharma for the exclusive rights for private
label version of Lumify in the US
OTHER
ANNOUNCEMENTS

5
Contents
2. Capital Market Performance – Pharmaceutical Industry

6
93%
85% 81% 86%
26%
100%
78%
60%
71%
43%
90%
60%
93%
67% 67%
89%
100%
5%
12% 12%
14%
36%
16%
20%
25%
36%
10%
35%
7%
11%
33%
11%
2% 3% 7%
38%
6%
20%
4%
21%
5%
22%
Buy Hold Sell
33 43 42
43 42 8 32 20 24 14 10 20 15 18 24
58%
73% 75%
88%
75% 75%
67%
50% 50%
100%
17%
8%
13%
50%
25% 20% 17%
25%
33%
50%
Buy Hold Sell
82% 75%
56%
83%
13%
22%
17%
18% 13%
22%
Buy Hold Sell
Updated Pharma Analysts’ Views On Indian Pharma Companies
Source: Bloomberg as of July 27, 2022
Indian Formulation Companies
Indian Entities of Global Pharma Companies API/CRAMS Companies
Total number of analysts covering the stock
12 8 4 4
24 3 2 2
9 2
11 8 9 6 15 4
25%

7
Listed Players – Indian Formulation Companies
Source: Bloomberg (July 27, 2022)
n.m. – Not Meaningful; n.a. – Not Available
EV is calculated based on net debt value of the latest fiscal ending
Company Name
Price M Cap EV EV/Revenue EV/EBITDA P/E
(INR) (USD mn) (USD mn) Mar 22 Mar 23 Mar 24 Mar 22 Mar 23 Mar 24 Mar 22 Mar 23 Mar 24
Sun Pharmaceutical Industries Ltd 943 28,548 27,499 5.7x 5.1x 4.6x 21.3x 19.1x 16.3x 66.8x 27.7x 23.6x
Cipla Ltd/India 977 9,950 9,598 3.5x 3.2x 2.9x 16.7x 14.8x 12.4x 31.0x 25.5x 20.9x
Dr Reddy's Laboratories Ltd 4,090 8,589 8,456 3.1x 2.9x 2.6x 16.2x 12.9x 10.9x 28.9x 20.5x 17.7x
Torrent Pharmaceuticals Ltd 1,529 6,527 6,971 6.6x 5.9x 5.2x 22.7x 19.6x 16.9x 66.6x 35.8x 28.8x
Gland Pharma Ltd 2,261 4,696 4,286 7.7x 7.4x 6.1x 22.5x 22.2x 17.6x 30.7x 30.1x 23.9x
Biocon Ltd 307 4,653 5,079 5.0x 3.7x 2.7x 20.4x 15.3x 10.1x 47.8x 34.7x 21.7x
Zydus Lifesciences Ltd 347 4,428 4,784 2.6x 2.3x 2.1x 11.8x 11.2x 9.9x 14.8x 17.1x 14.8x
Alkem Laboratories Ltd 3,225 4,865 4,885 3.7x 3.3x 3.0x 18.8x 17.7x 15.0x 22.9x 22.6x 19.0x
Aurobindo Pharma Ltd 547 4,043 3,826 1.3x 1.2x 1.1x 6.9x 6.3x 5.5x 12.1x 11.0x 9.6x
Lupin Ltd 644 3,694 3,985 2.0x 1.8x 1.6x n.m. 12.3x 9.7x n.m. 25.2x 18.0x
Ipca Laboratories Ltd 1,000 3,201 3,141 4.3x 3.9x 3.4x 19.0x 16.9x 14.1x 28.5x 26.2x 21.5x
Ajanta Pharma Ltd 1,279 2,067 2,028 4.9x 4.3x 3.8x 17.3x 15.9x 13.7x 23.0x 22.3x 19.2x
Alembic Pharmaceuticals Ltd 702 1,741 1,822 2.7x 2.5x 2.3x 16.5x 12.9x 10.8x 26.5x 19.5x 16.0x
JB Chemicals & Pharmaceuticals Ltd 1,770 1,726 1,726 5.6x 4.7x 4.1x 25.2x 19.5x 16.3x 35.4x 30.0x 24.2x
Natco Pharma Ltd 682 1,571 1,572 6.4x 4.2x 3.2x 47.3x 10.0x 6.7x 73.3x 15.6x 10.0x
Glenmark Pharmaceuticals Ltd 381 1,356 1,722 1.1x 1.1x 1.0x 5.9x 5.9x 5.3x 10.8x 9.9x 8.8x
Eris Lifesciences Ltd 678 1,164 1,155 6.9x 5.3x 4.6x 18.9x 16.0x 13.5x 22.7x 21.1x 17.7x
Caplin Point Laboratories Ltd 778 744 683 4.3x 3.8x 3.3x 13.7x 12.2x 10.6x 19.1x 17.7x 15.4x
FDC Ltd/India 254 531 467 2.4x 2.0x 1.7x 14.6x 8.1x 6.8x 19.5x 10.9x 9.3x
Indoco Remedies Ltd 385 448 478 2.5x 2.1x 1.9x 11.6x 10.6x 9.4x 22.9x 18.0x 14.7x
Strides Pharma Science Ltd 331 376 737 1.9x 1.5x 1.3x n.m. 12.6x 8.8x n.m. 35.4x 11.1x
Marksans Pharma Ltd 49 252 224 1.2x 1.1x 1.0x 6.9x 5.2x 4.4x 10.7x 7.9x 6.6x
Average 3.9x 3.3x 2.9x 17.7x 13.5x 11.1x 30.7x 22.0x 16.9x
Median 3.6x 3.3x 2.8x 17.0x 12.9x 10.7x 24.7x 21.7x 17.7x
TRADING COMPARABLES

8
Listed Players – Indian Formulation Companies
Company Name
Revenue (INR mn) Revenue Growth (YoY) EBITDA Margin PAT Margin RoCE RoE
Mar 22 Mar 23 Mar 24 Mar 22 Mar 23 Mar 24 Mar 22 Mar 23 Mar 24 Mar 22 Mar 23 Mar 24 Mar 22 Mar 22
Sun Pharmaceutical Industries Ltd 3,84,264 4,28,294 4,73,700 16.0% 11.5% 10.6% 26.7% 26.6% 28.2% 8.8% 19.1% 20.2% 19.4% 6.7%
Cipla Ltd/India 2,16,234 2,35,640 2,62,438 13.9% 9.0% 11.4% 21.1% 21.8% 23.3% 11.8% 13.1% 14.4% 20.0% 12.8%
Dr Reddy's Laboratories Ltd 2,14,391 2,31,533 2,54,972 13.0% 8.0% 10.1% 19.3% 22.4% 24.1% 11.0% 14.3% 15.0% 16.8% 12.9%
Torrent Pharmaceuticals Ltd 84,188 94,292 1,05,494 6.8% 12.0% 11.9% 28.9% 29.9% 31.0% 9.2% 15.3% 17.0% 18.1% 13.2%
Gland Pharma Ltd 44,007 45,652 55,763 27.1% 3.7% 22.1% 34.3% 33.5% 34.6% 27.5% 27.1% 28.0% 41.1% 18.6%
Biocon Ltd 80,248 1,07,545 1,50,026 14.5% 34.0% 39.5% 24.6% 24.4% 26.7% 9.6% 9.9% 11.3% 10.8% 8.6%
Zydus Lifesciences Ltd 1,48,276 1,61,535 1,76,858 5.0% 8.9% 9.5% 21.6% 21.0% 21.7% 16.0% 12.7% 13.4% 12.9% 14.0%
Alkem Laboratories Ltd 1,05,120 1,16,945 1,30,046 20.4% 11.2% 11.2% 19.5% 18.8% 19.8% 16.0% 14.6% 15.6% 21.9% 20.5%
Aurobindo Pharma Ltd 2,33,666 2,51,050 2,71,967 (4.9%) 7.4% 8.3% 18.8% 19.3% 20.2% 11.3% 11.6% 12.3% 14.6% 11.4%
Lupin Ltd 1,61,928 1,75,051 1,92,575 8.5% 8.1% 10.0% 1.4% 14.7% 16.9% (9.3%) 6.6% 8.5% (9.6%) n.m.
Ipca Laboratories Ltd 57,665 64,569 73,244 7.5% 12.0% 13.4% 22.7% 22.9% 24.1% 15.4% 15.0% 16.1% 23.3% 17.3%
Ajanta Pharma Ltd 32,841 37,666 42,184 15.4% 14.7% 12.0% 28.3% 26.9% 27.8% 21.7% 19.5% 20.2% 28.7% 22.8%
Alembic Pharmaceuticals Ltd 53,058 57,239 64,028 (1.5%) 7.9% 11.9% 16.5% 19.5% 21.0% 9.8% 12.3% 13.4% 10.7% 10.1%
JB Chemicals & Pharmaceuticals Ltd 24,242 29,323 33,077 21.1% 21.0% 12.8% 22.4% 23.9% 25.4% 15.9% 15.5% 17.1% 28.6% 19.5%
Natco Pharma Ltd 19,448 29,412 38,617 (5.2%) 51.2% 31.3% 13.5% 42.5% 48.1% 8.7% 27.2% 32.1% 2.9% 4.1%
Glenmark Pharmaceuticals Ltd 1,21,742 1,28,078 1,39,825 12.7% 5.2% 9.2% 19.1% 18.2% 18.5% 8.2% 8.5% 8.8% 16.0% 12.0%
Eris Lifesciences Ltd 13,262 17,266 19,925 11.2% 30.2% 15.4% 36.6% 33.2% 34.0% 30.6% 25.3% 26.2% 25.2% 23.3%
Caplin Point Laboratories Ltd 12,694 14,412 16,609 21.1% 13.5% 15.2% 31.1% 30.7% 30.7% 24.3% 23.1% 23.0% 39.7% 22.7%
FDC Ltd/India 15,279 18,661 21,797 15.5% 22.1% 16.8% 16.6% 24.4% 25.1% 14.1% 20.7% 20.8% 16.4% 11.7%
Indoco Remedies Ltd 15,037 17,767 19,822 23.4% 18.1% 11.6% 21.8% 20.1% 20.4% 10.3% 11.1% 12.2% 22.9% 18.5%
Strides Pharma Science Ltd 30,703 39,015 44,955 (7.4%) 27.1% 15.2% (0.3%) 11.9% 14.8% (15.4%) 2.2% 5.9% n.m. n.m.
Marksans Pharma Ltd 14,908 16,180 18,610 8.3% 8.5% 15.0% 17.4% 21.0% 21.7% 12.5% 15.6% 16.2% 25.0% 17.6%
Average 11.0% 15.7% 14.7% 21.0% 24.0% 25.4% 12.2% 15.5% 16.7% 19.3% 14.9%
Median 12.8% 11.7% 11.9% 21.3% 22.6% 24.1% 11.6% 14.8% 15.8% 19.4% 13.6%
OPERATING COMPARABLES

9
Listed Players – Indian Entities of Global Pharma Companies
Company Name
Abbott India Ltd 20,015 5,365 5,038 8.1x 7.2x 6.4x 36.7x 33.1x 29.0x 53.2x 47.4x 41.5x
GlaxoSmithKline Pharmaceuticals Ltd 1,406 3,005 2,648 6.4x 5.9x 5.3x 27.6x 24.9x 22.0x 62.6x 36.9x 32.4x
Pfizer Ltd 4,184 2,415 2,236 6.8x 6.3x 5.8x 21.2x 19.9x 17.9x 31.2x 30.3x 26.8x
Sanofi India Ltd 6,335 1,841 1,648 4.4x 4.4x n.a. 17.3x 17.4x n.a. 17.2x 25.6x n.a.
Company Name
Abbott India Ltd 49,103 55,427 62,786 14.0% 12.9% 13.3% 22.2% 21.8% 21.9% 16.3% 16.2% 16.3% 359.8% 29.5%
GlaxoSmithKline Pharmaceuticals Ltd 32,768 35,685 39,485 12.4% 8.9% 10.6% 23.3% 23.6% 24.1% 11.6% 18.1% 18.6% n.m. 18.4%
Pfizer Ltd 26,110 27,913 30,597 16.6% 6.9% 9.6% 32.0% 31.9% 32.4% 23.5% 22.6% 23.4% 46.2% 23.3%
Sanofi India Ltd 28,913 31,543 n.a. 1.7% 0.6% n.a. 25.7% 25.4% n.a. 28.8% 19.3% n.a. 80.9% 25.6%
Average 11.2% 7.3% 11.2% 25.8% 25.7% 26.1% 20.0% 19.1% 19.4% 162.3% 24.2%
Median 13.2% 7.9% 10.6% 24.5% 24.5% 24.1% 19.9% 18.7% 18.6% 80.9% 24.4%
TRADING COMPARABLES

10
Listed Players – API/CRAMS Companies
TRADING COMPARABLES
Notes: Above mentioned companies have presence across segments (Formulations, API, CRAM/ CDMO), they have been included in the formulations/ API category basis their largest revenue driver
Company Name
Divi's Laboratories Ltd 87,992 90,462 1,01,935 28.3% 2.8% 12.7% 44.1% 41.0% 41.5% 33.6% 29.7% 30.0% 44.5% 28.2%
Laurus Labs Ltd 48,885 63,256 71,522 3.5% 29.4% 13.1% 28.7% 31.7% 32.1% 17.0% 17.6% 18.0% 25.3% 27.9%
Syngene International Ltd 26,042 30,713 37,179 19.2% 17.9% 21.1% 28.5% 29.6% 31.1% 15.2% 15.4% 17.3% 15.2% 12.9%
Jubilant Ingrevia Ltd 49,144 53,238 60,943 618.3% 8.3% 14.5% 16.9% 16.6% 16.9% 9.7% 9.9% 10.5% 28.9% 21.9%
Granules India Ltd 37,649 42,994 49,099 16.3% 14.2% 14.2% 19.2% 19.7% 20.9% 11.0% 11.1% 12.4% 19.0% 17.3%
Glenmark Life Sciences Ltd 21,232 24,086 27,742 12.6% 13.4% 15.2% 29.0% 28.6% 29.0% 19.7% 19.9% 20.3% 53.0% 29.8%
Hikal Ltd 19,427 21,226 24,815 13.8% 9.3% 16.9% 17.5% 16.2% 17.8% 8.3% 6.7% 9.2% 15.4% 16.0%
Aarti Drugs Ltd 24,886 28,591 33,280 15.5% 14.9% 16.4% 13.2% 13.6% 15.0% 8.2% 8.3% 9.4% 19.9% 21.0%
Shilpa Medicare Ltd 11,455 12,727 14,088 27.1% 11.1% 10.7% 17.8% 0.1% 0.1% 5.3% 0.2% 0.2% 5.3% 3.7%
IOL Chemicals and Pharmaceuticals Ltd 21,840 24,466 26,321 11.0% 12.0% 7.6% 11.7% 14.0% 15.0% 7.6% 9.3% 9.9% 19.4% 12.5%
Dishman Carbogen Amcis Ltd 21,407 23,986 27,556 12.0% 12.0% 14.9% 15.5% 20.5% 21.3% 0.8% 4.6% 6.0% 0.3% 0.3%
Solara Active Pharma Sciences Ltd 12,683 15,796 17,555 (21.6%) 24.5% 11.1% 6.3% 12.8% 16.9% (4.6%) 1.7% 6.3% n.m. n.m.
Neuland Laboratories Ltd 9,511 10,829 12,649 1.5% 13.9% 16.8% 15.0% 15.8% 16.6% 6.7% 7.6% 8.5% 9.5% 7.8%
Average 58.3% 14.1% 14.2% 20.3% 20.0% 21.1% 10.7% 10.9% 12.1% 21.3% 16.6%
Median 13.8% 13.4% 14.5% 17.5% 16.6% 17.8% 8.3% 9.3% 9.9% 19.2% 16.7%
Company Name
Divi's Laboratories Ltd 3,832 12,832 12,477 11.2x 10.9x 9.7x 25.5x 26.7x 23.4x 34.4x 37.9x 33.3x
Laurus Labs Ltd 523 3,543 3,759 6.1x 4.7x 4.2x 21.2x 14.9x 13.0x 33.8x 25.2x 21.8x
Syngene International Ltd 568 2,872 2,839 8.6x 7.3x 6.1x 30.4x 24.7x 19.5x 57.5x 48.2x 35.4x
Jubilant Ingrevia Ltd 530 1,065 1,089 1.8x 1.6x 1.4x 10.4x 9.8x 8.4x 17.7x 16.0x 13.2x
Granules India Ltd 300 939 1,027 2.2x 1.9x 1.7x 11.3x 9.6x 7.9x 18.0x 15.6x 12.2x
Glenmark Life Sciences Ltd 464 717 653 2.4x 2.1x 1.9x 8.4x 7.5x 6.4x 13.6x 11.8x 10.1x
Hikal Ltd 252 391 469 1.9x 1.8x 1.5x 10.9x 10.8x 8.4x 19.3x 21.9x 13.7x
Aarti Drugs Ltd 419 489 555 1.8x 1.5x 1.3x 13.4x 11.3x 8.8x 18.9x 16.3x 12.4x
Shilpa Medicare Ltd 412 451 531 3.7x 3.3x 3.0x 20.7x n.m. n.m. 59.0x n.m. n.m.
IOL Chemicals and Pharmaceuticals Ltd 357 264 252 0.9x 0.8x 0.8x 7.8x 5.8x 5.1x 12.7x 9.2x 8.0x
Dishman Carbogen Amcis Ltd 127 250 423 1.6x 1.4x 1.2x 10.1x 6.8x 5.7x n.m. 18.1x 12.1x
Solara Active Pharma Sciences Ltd 383 174 297 1.9x 1.5x 1.3x 29.3x 11.6x 7.9x n.m. 52.6x 12.4x
Neuland Laboratories Ltd 1,301 211 238 2.0x 1.7x 1.5x 13.2x 11.0x 9.0x 26.2x 20.3x 15.5x

11
Contents
2. Performance – Pharmaceutical Industry

12
About Us – Edelweiss Group
EDELWEISS GROUP
The Edelweiss Group is one of India's leading diversified financial services company providing a broad range of financial products
and services to a substantial and diversified client base that includes corporations, institutions and individuals. Edelweiss’
products and services span multiple asset classes and consumer segments across domestic and global geographies. Its
businesses are broadly divided into:
 EWM – Investment Banking, Institutional Equities, Wealth Management, etc.
 EAM - Edelweiss Asset Management
 Credit Business - Structured Collateralized Credit to Corporates, Real Estate Finance and Distressed Assets Credit; Retail
Credit including Housing Finance, LAP, LAS, SME & Agri Finance, and Rural Finance
 Life Insurance - JV with Tokyo Life of Japan
2 5 + years of experience
475 offices in India
1 . 2 m n + clients
1 0 , 0 0 0 + business professionals
INVESTMENT BANKING CAPABILITIES
M&A Advisory – Robust M&A practice and a cross-border network spanning 30+ countries
PE Advisory – Pioneer in PE Advisory; has a long standing relationship with most PE funds
Equity Capital Markets – Market leader in IPOs and Institutional Placements (QIPs, Blocks etc.)
Debt Capital Markets– Most active player in Fixed Income capital markets and debt syndication
Institutional Equities – Largest team on the street with 225+ stocks under coverage
INR 2,49,100 c r + total AUM
INR 1,45,000 c r wealth managed
1 0 0 + dedicated investment
banking professionals
5 sector focused teams
 Consumer & Healthcare
 Infra and Real Estate
 TMTE
 General Industrials
 Financial Institutions
Edelweiss Wealth Management
Investment Banking
 Oldest business for Edelweiss Group
 Amongst the largest IPO distributors in the
country
 Full Service Investment bank providing ECM,
DCM and advisory services across sectors and
products
Institutional Equities
 Awarded as ‘Best Broker’ in India in ‘Finance
Asia Country Awards 2020’
 75+ analysts covering 325+ stocks for
institutional and non-institutional investors
 Differentiated products by alternative &
quants research teams
Wealth Management
 Amongst top 3 wealth management practices
in India
 Client assets ~INR 1,450 bn (Q3 FY 21)
 Awarded as ‘Best Wealth Manager’ in ‘Asian
Private Banker’ 2018 and 2019

13
Edelweiss has completed 340+ deals worth $ 85bn+ since April 2014
SELECT MARQUEE TRANSACTIONS
Above is a select list of deals
IPO
INR 412 crs
Left Lead BRLM
February 2021
INR 2,500 crs
BRLM
April 2021
INR 7,735 crs
BRLM
April 2021
INR 1,838 crs
BRLM
August 2021
INR 1,895 crs
BRLM
September 2021
INR 800 crs
BRLM
November 2021
INR 2,780 crs
BRLM
August 2021
INR 1,024 crs
BRLM
November 2021
INR 1,398 crs
BRLM
December 2021
INR 3,185 crs
BRLM
February 2022
Sell side M&A for sale of
solar portfolio
~INR 1,554 crs
Sole Financial Advisor
April 2020
Sale of Stake in Mumbai
Airport to Adani Group
INR 675 crs
Sole Sell Side Advisor
February 2021
Acquired by Wipro
Enterprises
March 2021
Acquired by Apax Partners
March 2021
Acquired by eClerx Services
March 2021
Advisory
Acquired 40% Stake in
Sterling and Wilson Solar
Buy Side Advisor
October 2021
QIPs l Blocks | Rights | OFS
QIP
INR 300 crs
Left Lead BRLM
June 2021
QIP
INR 3,788 crs
BRLM
December 2020
Promotor Block Placement
INR 160 crs
Sole Broker
February 2021
QIP
INR 1,800 crs
BRLM
May 2021
QIP
INR 1,200 crs
Left Lead BRLM
June 2021
OFS
~INR 160 crs
Broker
June 2021
Promoter Block
INR 200 crs
BRLM
September 2021
QIP
INR 868 crs
BRLM
September 2021
QIP
INR 1,402 crs
BRLM
February 2022
Open Offer
INR 153 crs
Manager to the offer
May 2022
Sale of Highway asset to
Announced
Fund Raise from
April 2022
Merger with
Financial Advisor
Announced
Acquisition of
Buy Side Advisor
June 2022

14
SELECT TRANSACTIONS
Natco Pharma
Qualified Institutions Placement
BRLM
INR 915 crs
Shalby Limited
Initial Public Offering
Global Coordinator and BRLM
(Left Lead)
INR 505 crs
Alkem Laboratories
Global Coordinator and BRLM
INR 1,348 crs
HealthCare Global Enterprises
BRLM
INR 650 crs
Alkem Laboratories
Block Placement
Sole Broker
~INR 480 crs
Laurus Labs
Block Placement
Sole Broker
~INR 300 crs
BRLM - Ongoing
Undisclosed
Thyrocare Technologies
BRLM
INR 479 crs
Rich Transaction Experience in the Healthcare Space
BRLM - Ongoing
Undisclosed
BRLM
INR 1,895 crs
BRLM
INR 1,024 crs
Orchid Pharma Limited
OFS by Dhanuka Laboratories
Seller Broker
INR 160 crs
BRLM
INR 1,398 crs
Alembic Ltd.
De-merger of Alembic Pharma
Undisclosed
Leading Healthcare Services
Chain
BRLM - Ongoing
Undisclosed

15
Disclaimer
For our investment banking page, please refer to: https://www.edelweissfin.com/web/edelweiss/investment-banking
https://www.edelweissfin.com/web/edelweiss/investment-banking
s://www.edelweissfin.com/web/edelweiss/investment-banking
This Information Package is distributed by Edelweiss Financial Services Limited (hereinafter “Edelweiss”) on a strictly private and confidential and on a need to know basis exclusively to intended
recipient. This Information Package and the information and projections contained herein may not be disclosed, reproduced or used in whole or in part for any purpose or furnished to any other
person or persons. The Persons who are in possession of this Information package or may come in possession at a later day, hereby undertakes to observe the restrictions contained herein.
The information contained herein is of a general nature and is not intended to address the facts and figures of any particular individual or entity. The content provided here treats the subjects
covered here in condensed form. It is intended to provide a general guide to the subject matter and should not be relied on as a basis for business decisions. No one should act upon such
information without making appropriate additional professional advice after a thorough examination of the particular situation. This Information Package is distributed by Edelweiss upon the
express understanding that no information herein contained has been independently verified. Further, no representation or warranty expressed or implied is made nor is any responsibility of any
kind accepted with respect to the completeness or accuracy of any information as may be contained herein. Also no representation or warranty expressed or implied is made that such
information remains unchanged in any respect as of any date or dates after those stated herein with respect to any matter concerning any statement made in this Information Package. Edelweiss
and its directors, employees, agents and consultants shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions,
information or matters (express or implied) arising out of, contained in or derived from, or for any omissions from the Information Package and any liability whatsoever for any direct, indirect,
consequential or other loss arising from any use of this information package and/or further communication in relation to this information package.
All recipients of the Information Package should make their own independent evaluations and should conduct their own investigation and analysis and should check the accuracy, reliability and
completeness of the Information and obtain independent and specific advice from appropriate professional advisers, as they deem necessary. Where this Information Package summarizes the
provisions of any other document, that summary should not be relied upon and the relevant.
The information contained in this document is confidential in nature and the recipient is receiving all such information on the express condition of confidentiality unless expressly authorized in
writing by Edelweiss.
If you are not the intended recipient, you must not disclose or use the information in this document in any way whatsoever. If you received it in error, please inform us immediately by return e-
mail and delete the document with no intention of its being retrieved by you. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to
them by any other person.
Satyen Shah (20+ yrs)
MD & Head – Advisory
Tel: +91 22 4086 3516
satyen.shah@edelweissfin.com
Gopal Agrawal (22+ yrs)
MD & Head – Investment Banking
Tel: +91 22 4272 2139
gopal.agrawal@edelweissfin.com
Contact information for
Follow our LinkedIn page for interesting updates, announcements and insights: https://www.linkedin.com/showcase/edelweiss-investment-banking.
Subodh Gupta (20+ yrs)
MD & Head – M&A, Consumer and
Healthcare
Tel: +91 22 4088 6390
subodh.gupta@edelweissfin.com
Priti Sahay (7+ yrs)
VP - Healthcare
Tel: +91 22 4079 5086
priti.sahay@edelweissfin.com
Ravi Kumar (20+ yrs)
MD & Head – Pharma
Tel: +91 44 4022 1255
k.ravikumar@edelweissfin.com

Indian Pharmaceutical Monthly Update July 2022.pdf

More Related Content

Similar to Indian Pharmaceutical Monthly Update July 2022.pdf

Recently uploaded

Indian Pharmaceutical Monthly Update July 2022.pdf